Table 3.

Practical issues affecting design of trials for assessing SAbR in oligometastatic disease

Trial design challenges
Defining oligometastatic cohort with relatively similar prognosis for study screening
Maintaining safety as a primary focus
Prescribing allowable therapies that allow reproducibility in multi-institution setting
Picking achievable clinical end points or surrogate measures that assess meaningful clinical benefit
Collaborative efforts often needed to synthesize technical approaches and attain sufficient power
Setting control cohorts to fairly assess efficacy of intervention and its costs